HCW Biologics Inc

HCW Biologics launches first‑in‑human trial of its IL‑2 fusion immunotherapy for alopecia areata, but faces high‑risk financial and competitive challenges.

HCW Biologics Inc. is a biopharmaceutical company focused on developing innovative immunotherapy treatments to address chronic inflammation and age-related diseases.

HCW Biologics Inc. has announced a $5 million follow-on offering, sparking a 16% surge in its stock price, as the company continues to pursue growth and innovation in the biopharmaceutical industry.